Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart
The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.

Pharmaceutical Technology

In recent years, there have been numerous articles written about requirements to meet good manufacturing practices (GMPs) for excipient and active pharmaceutical ingredient (API) manufacture. This article, however, highlights some of the differences between auditing an excipient manufacturer and a manufacturer of APIs.

There are significant differences between companies and facilities that produce these two types of ingredients. Companies that manufacture an active ingredient are often manufacturers who produce it with support from their customer. In cases where there is an active patent situation, the manufacturer typically will have just one customer and be expected to work closely with that customer to meet its needs for product quality and quality-system conformance. In situations where the API is no longer protected by patent, the API manufacturer may provide product to more than one customer. An API facility seldom provides the material it manufactures for use in nonpharmaceutical markets so the requirements of the pharmaceutical industry drive conformance to quality-system requirements.

This situation contrasts with excipient manufacturers who typically produce ingredients for general use for multiple industries such as food and industrial applications. Because some common excipients are used broadly in the pharmaceutical industry, the manufacturer would be expected to have many pharmaceutical customers in multiple industries. Excipient ingredients are used in other industries, usually on a larger scale. Although excipient applications provide an important source of profit, other markets often provide a greater revenue stream. The excipient manufacturer is thus driven to produce material in a cost-effective manner without adversely affecting its competitive position in those other market applications.

Customer audits

API manufacturers recognize that hosting customer audits are a necessary cost of doing business and generally anticipate that their customers will periodically visit the facility. However, excipient manufacturers are often reluctant to host an audit except for important customers because they could not feasibly accommodate their large customer base if each customer requested a site visit. In addition, API auditors customarily spend more days in a plant than an excipient manufacturer can manage.

Typically, API facilities are dedicated to the production of active ingredients whereas most excipient plants produce more nonpharmaceutical-grade products than products that will be used as pharmaceutical excipients. Where API equipment is often used for different ingredients, the production of excipients is usually in equipment dedicated to that type of material (e.g., pharmaceutical, food, industrial grade). This reduction in complexity at excipient manufacturers consequently reduces the time required for assessing excipient GMP conformance.

Another difference between the two types of ingredients manufacturers is the need to ascertain the point within the process where full GMP requirements are expected to be applied. Generally speaking, because facilities that produce APIs do not sell the ingredients for use in other markets, the expectation is that full GMPs apply earlier in the process than for excipient manufacturers where production of nonpharmaceutical grades can occur interchangeably.

Contamination concerns

A significant risk of contamination to active ingredients results from the use of nondedicated equipment and facilities, especially when the equipment is used to produce other APIs. Thus, there is emphasis in API GMP requirements for adequate cleaning of both the equipment and facilities. The source of contamination to excipients is very different because their manufacture usually occurs in dedicated equipment and related facilities. An important contamination risk to the excipient can occur, however, when the excipient is exposed to the environment, which can contain contaminants from other nearby processing operations. Although the excipient auditor should assure the adequacy of procedures for cleaning equipment and related facilities, the auditor must also assess the risk to the excipient from environmental contamination.

Exposure of employees to an API can result in an adverse pharmacological effect. For this reason, API packaging is performed in a room under negative pressure to contain the ingredient. Exposure to an excipient, on the other hand, does not generally present an imminent health risk to the worker. Because it is undesirable to expose excipients to airborne contaminants at packaging, it is customary to have the packaging enclosure under positive pressure with filtered air to keep out such undesirables.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here